Endo intros generic Dexilant

Endo’s Par unit is offering dexlansoprazole 30 mg capsules, which is the generic of Takeda's Dexilant.

This additional dosage strength rounds out the product family, now with both 30 mg and 60 mg delayed-release capsules, the company said.

"We're proud to provide this high-quality, affordable generic medication to appropriate patients," said Scott Sims, senior vice president and general manager of injectable solutions and generics at Endo. "The dexlansoprazole product family strengthens our portfolio and our reputation as a reliable supplier."

[Read more: Endo to distribute bivalirudin injection in ready-to-use vials]

Dexlansoprazole is a proton pump inhibitor with a novel delivery system approved for the treatment of erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease.

[Read more: Par launches generic Pylera]

Dexilant 30 mg had a market value of approximately $45 million for the 12 months ended April 30, 2023, per IQVIA.